FENNEC PHARMACEUTICALS INC. (FENC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 12.39M USD | Liabilities, Current |
| Cash and equivalents | 41.25M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $12.39M | $41.25M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $9.59M | $40.18M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $10.52M | $36.79M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $9.81M | $21.95M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $8.41M | $18.70M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $8.37M | $22.68M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $6.92M | $26.63M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $7.43M | $40.32M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $7.75M | $43.05M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $9.84M | $51.18M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $7.55M | $13.27M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $3.91M | $12.40M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $3.78M | $14.96M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.02M | $18.39M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $4.61M | $23.77M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $2.93M | $29.75M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $3.04M | $14.91M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.14M | $18.26M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.65M | $21.10M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.01M | $24.34M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $848.00K | $27.29M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $2.89M | $26.75M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.35M | $30.34M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $2.88M | $33.17M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $3.19M | $38.73M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.91M | $9.90M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.27M | $13.65M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $905.00K | $15.24M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.35M | $17.48M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $1.45M | $20.23M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $1.64M | $22.78M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.08M | $24.52M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $847.00K | $25.64M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $1.17M | $26.72M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $1.64M | $28.26M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $1.03M | $9.69M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $580.00K | $10.23M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $427.00K | $3.25M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $402.00K | $3.93M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $360.00K | $4.54M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $451.00K | $5.08M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $345.00K | $545.00K | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $471.00K | $942.00K | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $431.00K | $1.37M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $759.00K | $1.85M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $1.12M | $1.92M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.76M | $2.31M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $3.90M | $593.00K | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $5.71M | $1.01M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $5.73M | $1.34M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $3.21M | $1.66M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $538.00K | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $1.01M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $11.00M | $1.90M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $7.32M | $2.30M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $2.86M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $3.59M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $4.72M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $5.47M | $5.30M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | $6.17M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $6.81M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $5.02M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $5.95M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $6.60M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $7.15M | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $348.00K | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $685.00K | (m) | (m) | (m) | (m) |
| 1996-09-02 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |